PREVENTion of Clot in Orthopaedic Trauma


Principal Investigators: Robert O’Toole, MD, Deborah M. Stein, MD, MPH and Renan Castillo, PhD


The PREVENT CLOT study, which is short for PREVENTion of Clot in Orthopaedic Trauma (PREVENT CLOT): A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopaedic Trauma Patients, is funded by the Patient Centered Outcomes Research Institute. The study is being conducted in collaboration with the Major Extremity Trauma Rehabilitation Consortium. We are enrolling 12,000 patients at 18 trauma centers around the United States and Canada, including military centers that are taking care of service members who were injured in the line of duty. Clinical Identifier: NCT02984384.

People who have surgery or trauma are at risk for blood clots. The purpose of this research study is to help figure out the best way to prevent blood clots after trauma. Blood clots can be very serious and can lead to death. Right now, doctors use two different medicines to prevent blood clots, but they don’t know which one is better. One of these medicines to prevent blood clots is called low molecular weight heparin, or Lovenox. The other medicine doctors sometimes use is aspirin. This study is being done to find out whether low molecular weight heparin (Lovenox/Enoxaparin) or aspirin is better in preventing life threatening blot clots in trauma patients. Patients who join this study will get either the low molecular weight heparin (Lovenox/Enoxaparin) or aspirin to prevent blood clots. The low molecular weight heparin (Lovenox/Enoxaparin) is given by injection (shot). The aspirin is a pill taken by mouth or given through a feeding tube. Patients in this study will start their medicine in the hospital and then take the same medicine once they go home. We will then compare the medicines to see which one was better at preventing blood clots.